Siegfried inaugurates its new Development Center for Drug Products at its two Spanish sites in Barberà del Vallès and El Masnou near Barcelona (Spain).

The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network.

At this new facility, 40 highly skilled specialists will work closely with Siegfried's customers to bring their precious innovations to industrial scale. The Development Center will play a key role in providing the pharmaceutical industry with services from development to commercial production.

The Development Center includes dedicated facilities for highly potent oral solid dosage forms, which will allow Siegfried to offer development services and flexible pilot capacities for this important and growing market segment.

The Development Center with advanced laboratories and pilot capacities was built over the past two years and will be serving a diverse range of customers. With this opening, Siegfried concludes the successful integration of the two sites.

The two pharmaceutical manufacturing sites acquired from Novartis at the beginning of 2021, Barberà del Vallès and El Masnou, have been fully integrated into the Siegfried network In 2022.

Wolfgang Wienand, CEO of Siegfried: "The new Development Center in Barcelona strengthens our global network and supports our growth strategy. This significant investment underpins our commitment to providing customers with the most advanced skills and capabilities for the development and manufacturing of Drug Products. It is an important step towards our vision of being the leading CDMO in our space and becoming the most trusted partner of the pharmaceutical industry."

In a year of macroeconomic uncertainties, Siegfried demonstrated its resilience and delivered a strong performance for the full year 2022. Net sales reached 1.229 billion Swiss francs (CHF), an increase of 15.6 percent in local currencies (2021: CHF 1.102 billion), supported by both, Drug Substances and Drug Products. Core EBITDA grew from CHF 207.2 million to now CHF 272.5 million, 31.5 percent higher than 2021.